DUALOGICS - ORTHOMAB
OrthoMab is an operator of a bispecific platform dedicated to creating improved antibody therapies. The company specializes in producing antibodies using standard production and purification techniques which are available in flexible formats that can be tailored to specific target biology and mechanisms of action.
DUALOGICS - ORTHOMAB
Industry:
Biotechnology Therapeutics
Address:
Durham, North Carolina, United States
Country:
United States
Status:
Active
Similar Organizations
Curionic Biotherapeutics
Curionic Biotherapeutics develops a platform technology designed to discover protein therapeutics.
ERAD Therapeutics
ERAD Therapeutics is a developer of a drug platform designed to create novel biological agents to treat orphan diseases
More informations about "Dualogics - OrthoMab"
AbCellera Acquires OrthoMab Bispecific Platform to Propel the ...
Aug 20, 2020 VANCOUVER, British Columbia, August 20, 2020 – AbCellera today announced the acquisition of the OrthoMab bispecific platform from Dualogics, LLC. (Dualogics). …See details»
Dualogics (OrthoMab) 2025 Company Profile: Valuation, Investors ...
Dualogics (OrthoMab) General Information Description. Operator of a bispecific platform dedicated to create improved antibody therapies. The company specializes in producing …See details»
Dualogics Sells Antibody Platform to Canadian Company
Aug 20, 2020 Durham-based Dualogics has sold its core technology for producing therapeutic antibodies to a Canadian biotechnology company.. Under the terms of the asset purchase agreement, AbCellera of Vancouver, British …See details»
Durham startup Dualogics sells platform for producing …
Aug 20, 2020 The Biotech Center also provided a loan to Dualogics in 2018 for $250,000. Dualogics has subsequently been supported by grants from the …See details»
AbCellera acquires OrthoMab bispecific platform from …
Under the terms of the asset purchase agreement, AbCellera acquires full rights to the OrthoMab platform and Dualogics retains rights to develop existing …See details»
AbCellera acquires Dualogics - OrthoMab - 2020-08-20
Aug 20, 2020 Dualogics - OrthoMab OrthoMab is an operator of a bispecific platform dedicated to creating improved antibody therapies. Acquiring Organization: AbCellera AbCellera is an …See details»
Dualogics - OrthoMab - Crunchbase
OrthoMab is an operator of a bispecific platform dedicated to creating improved antibody therapies.See details»
Dualogics - OrthoMab - Crunchbase Company Profile & Funding
OrthoMab is an operator of a bispecific platform dedicated to creating improved antibody therapies. The company specializes in producing antibodies using standard production and …See details»
AbCellera Acquires OrthoMab Bispecific Platform to Propel the ...
Aug 20, 2020 AbCellera today announced the acquisition of the OrthoMab bispecific platform from Dualogics. Dr. Tim Jacobs CTO of Dualogics joins AbCellera’s team.See details»
AbCellera’s Acquisition of OrthoMab Bispecific Platform Propels ...
Aug 28, 2020 AbCellera has acquired the OrthoMab bispecific platform from Dualogics, a US-based biotechnology company specializing in protein engineering for improving antibody …See details»
AbCellera acquires OrthoMab bispecific platform
Aug 25, 2020 Under the terms of the asset purchase agreement, AbCellera acquires full rights to the OrthoMab platform and Dualogics retains rights to develop existing internal assets and to complete existing partnership …See details»
Lilly partner AbCellera adds bispecifics platform to antibody …
Aug 21, 2020 Under the deal, AbCellera has full rights to the OrthoMab technology, while Dualogics holds onto the rights to develop its own programs based on the platform, as well as …See details»
AbCellera acquires OrthoMab bispecific platform from Dualogics
Aug 25, 2020 AbCellera announced the acquisition of the OrthoMab bispecific platform from Dualogics, LLC. (Dualogics). OrthoMab is a clinically validated platform that uses the most …See details»
Dualogics 2025 Company Profile: Valuation, Funding & Investors
Dualogics General Information Description. Operator of a research and development company intended to develop bi-specific antibodies targeting oncology and autoimmune disease. The …See details»
AbCellera Acquires OrthoMab Bispecific Platform to Propel the ...
Aug 20, 2020 VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera today announced the acquisition of the OrthoMab bispecific platform from Dualogics, LLC.(Dualogics). OrthoMab …See details»
Dualogics LLC - VentureRadar
Dualogics is a biotechnology company using proprietary technology to develop bispecific antibodies with superior properties to those generated using other methods. The University of …See details»
Durham’s Dualogics, Y-Biologics Collaborate on ‘Bispecific’ Cancer ...
Aug 21, 2019 Dualogics’ technology, called OrthoMab, allows scientists to expand on the benefits of monoclonal antibodies by making so-called “bispecific” antibodies – a relatively new …See details»
Dualogics - Crunchbase Company Profile & Funding
Dualogics is a biotechnology company housed at the University of North Carolina at Chapel Hill. Dualogics uses a proprietary bispecific antibody technology to create bispecific antibody …See details»
Dualogics Company Profile - Office Locations, Competitors, …
Dualogics is a company specializing in protein engineering. It develops protein-based therapies for patients suffering from autoimmune diseases and cancers.See details»
AbCellera Acquires OrthoMab Bispecific Platform to Propel the ...
Aug 25, 2020 AbCellera today announced the acquisition of the OrthoMab bispecific platform from Dualogics, LLC. (Dualogics). OrthoMab is a clinically validated platform that uses the …See details»